Anthony David Sedgwick

Cambridge Biotechnology Ltd. is a wholly owned subsidiary of Biovitrum AB. The company's founders originate from a Pfizer Global Research & Development drug discovery team in what had previously been the Parke-Davis Neuroscience Research Centre. The founders, together with some key academic collaborators, created the company to exploit several opportunities in drug discovery as well as their world class 'gene to lead' drug discovery capability. The company has well equipped modern laboratory and office facilities situated on the Babraham Research Campus. This location allows the company to forge links with a host of world class research groups based in the Cambridge area. CBT is always looking to identify potential partner companies for both in-licensing and risk-sharing drug discovery ventures.

Microvisk Ltd. engages in the manufacture and development of micro-viscometer based on micro electro mechanical sensors technology for medical field. The firm's products include CoagMax, CoagLite, CoagManager and SmartStrip. It develops technology for the detection and analysis of a fluid's properties using a cantilever-based micro-viscometer. The company was founded by Vladislav Djakov, Paul Morgan Vernon and Jeremy Burford Peckham in 2004 and is headquartered in Oxford, the United Kingdom.

Roche Holding (UK) Ltd. manufactures and sells drugs. It operates as a holding company for Roche Products Ltd. and Roche Diagnostics Ltd. Its pharmaceuticals include Copegus, a hepatitis C therapy, HIV inhibitor Fuzeon, and breast cancer therapy, Herceptin. The firm's consumer and professional tests include Accutrend glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics. The company was founded in 1908 and is headquartered in Welwyn Garden City, UK.

Summit (Cambridge) Ltd. develops and manufactures drugs and pharmaceuticals. It discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases. The company was founded in 2001 by Paul Goldsmith and Mark Carlton and is headquartered in Cambridge, the United Kingdom.

Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom.